Eintrag weiter verarbeiten
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance
Gespeichert in:
| Zeitschriftentitel: | Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Cancer Research, 78, 2018, 1, S. 265-277 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei |
|---|---|
| author |
Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei |
| spellingShingle |
Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei Cancer Research A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance Cancer Research Oncology |
| author_sort |
arnst, kinsie e. |
| spelling |
Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-17-0577 <jats:title>Abstract</jats:title> <jats:p>Antimitotics that target tubulin are among the most useful chemotherapeutic drugs, but their clinical activity is often limited by the development of multidrug resistance. We recently discovered the novel small-molecule DJ101 as a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors. In this study, we determined the mechanism of action of this drug. The basis for its activity was illuminated by solving the crystal structure of DJ101 in complex with tubulin at a resolution of 2.8Å. Investigations of the potency of DJ101 in a panel of human metastatic melanoma cell lines harboring major clinically relevant mutations defined IC50 values of 7–10 nmol/L. In cells, DJ101 disrupted microtubule networks, suppressed anchorage-dependent melanoma colony formation, and impaired cancer cell migration. In melanoma-bearing mice, DJ101 administration inhibited tumor growth and reduced lung metastasis in the absence of observable toxicity. DJ101 also completely inhibited tumor growth in a paclitaxel-resistant xenograft mouse model of human prostate cancer (PC-3/TxR), where paclitaxel was minimally effective. Our findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation tubulin inhibitor for cancer therapy.</jats:p> <jats:p>Significance: These findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation antitubulin drug for cancer therapy. Cancer Res; 78(1); 265–77. ©2017 AACR.</jats:p> A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance Cancer Research |
| doi_str_mv |
10.1158/0008-5472.can-17-0577 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE3LTA1Nzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE3LTA1Nzc |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
American Association for Cancer Research (AACR), 2018 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2018 |
| issn |
0008-5472 1538-7445 |
| issn_str_mv |
0008-5472 1538-7445 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
arnst2018apotentmetabolicallystabletubulininhibitortargetsthecolchicinebindingsiteandovercomestaxaneresistance |
| publishDateSort |
2018 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Research |
| source_id |
49 |
| title |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_unstemmed |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_full |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_fullStr |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_full_unstemmed |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_short |
A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_sort |
a potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/0008-5472.can-17-0577 |
| publishDate |
2018 |
| physical |
265-277 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Antimitotics that target tubulin are among the most useful chemotherapeutic drugs, but their clinical activity is often limited by the development of multidrug resistance. We recently discovered the novel small-molecule DJ101 as a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors. In this study, we determined the mechanism of action of this drug. The basis for its activity was illuminated by solving the crystal structure of DJ101 in complex with tubulin at a resolution of 2.8Å. Investigations of the potency of DJ101 in a panel of human metastatic melanoma cell lines harboring major clinically relevant mutations defined IC50 values of 7–10 nmol/L. In cells, DJ101 disrupted microtubule networks, suppressed anchorage-dependent melanoma colony formation, and impaired cancer cell migration. In melanoma-bearing mice, DJ101 administration inhibited tumor growth and reduced lung metastasis in the absence of observable toxicity. DJ101 also completely inhibited tumor growth in a paclitaxel-resistant xenograft mouse model of human prostate cancer (PC-3/TxR), where paclitaxel was minimally effective. Our findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation tubulin inhibitor for cancer therapy.</jats:p>
<jats:p>Significance: These findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation antitubulin drug for cancer therapy. Cancer Res; 78(1); 265–77. ©2017 AACR.</jats:p> |
| container_issue |
1 |
| container_start_page |
265 |
| container_title |
Cancer Research |
| container_volume |
78 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348186235371523 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:06:44.587Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+Potent%2C+Metabolically+Stable+Tubulin+Inhibitor+Targets+the+Colchicine+Binding+Site+and+Overcomes+Taxane+Resistance&rft.date=2018-01-01&genre=article&issn=1538-7445&volume=78&issue=1&spage=265&epage=277&pages=265-277&jtitle=Cancer+Research&atitle=A+Potent%2C+Metabolically+Stable+Tubulin+Inhibitor+Targets+the+Colchicine+Binding+Site+and+Overcomes+Taxane+Resistance&aulast=Li&aufirst=Wei&rft_id=info%3Adoi%2F10.1158%2F0008-5472.can-17-0577&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348186235371523 |
| author | Arnst, Kinsie E., Wang, Yuxi, Hwang, Dong-Jin, Xue, Yi, Costello, Terry, Hamilton, David, Chen, Qiang, Yang, Jinliang, Park, Frank, Dalton, James T., Miller, Duane D., Li, Wei |
| author_facet | Arnst, Kinsie E., Wang, Yuxi, Hwang, Dong-Jin, Xue, Yi, Costello, Terry, Hamilton, David, Chen, Qiang, Yang, Jinliang, Park, Frank, Dalton, James T., Miller, Duane D., Li, Wei, Arnst, Kinsie E., Wang, Yuxi, Hwang, Dong-Jin, Xue, Yi, Costello, Terry, Hamilton, David, Chen, Qiang, Yang, Jinliang, Park, Frank, Dalton, James T., Miller, Duane D., Li, Wei |
| author_sort | arnst, kinsie e. |
| container_issue | 1 |
| container_start_page | 265 |
| container_title | Cancer Research |
| container_volume | 78 |
| description | <jats:title>Abstract</jats:title> <jats:p>Antimitotics that target tubulin are among the most useful chemotherapeutic drugs, but their clinical activity is often limited by the development of multidrug resistance. We recently discovered the novel small-molecule DJ101 as a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors. In this study, we determined the mechanism of action of this drug. The basis for its activity was illuminated by solving the crystal structure of DJ101 in complex with tubulin at a resolution of 2.8Å. Investigations of the potency of DJ101 in a panel of human metastatic melanoma cell lines harboring major clinically relevant mutations defined IC50 values of 7–10 nmol/L. In cells, DJ101 disrupted microtubule networks, suppressed anchorage-dependent melanoma colony formation, and impaired cancer cell migration. In melanoma-bearing mice, DJ101 administration inhibited tumor growth and reduced lung metastasis in the absence of observable toxicity. DJ101 also completely inhibited tumor growth in a paclitaxel-resistant xenograft mouse model of human prostate cancer (PC-3/TxR), where paclitaxel was minimally effective. Our findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation tubulin inhibitor for cancer therapy.</jats:p> <jats:p>Significance: These findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation antitubulin drug for cancer therapy. Cancer Res; 78(1); 265–77. ©2017 AACR.</jats:p> |
| doi_str_mv | 10.1158/0008-5472.can-17-0577 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE3LTA1Nzc |
| imprint | American Association for Cancer Research (AACR), 2018 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2018 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 0008-5472, 1538-7445 |
| issn_str_mv | 0008-5472, 1538-7445 |
| language | English |
| last_indexed | 2024-03-01T18:06:44.587Z |
| match_str | arnst2018apotentmetabolicallystabletubulininhibitortargetsthecolchicinebindingsiteandovercomestaxaneresistance |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 265-277 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Research |
| source_id | 49 |
| spelling | Arnst, Kinsie E. Wang, Yuxi Hwang, Dong-Jin Xue, Yi Costello, Terry Hamilton, David Chen, Qiang Yang, Jinliang Park, Frank Dalton, James T. Miller, Duane D. Li, Wei 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-17-0577 <jats:title>Abstract</jats:title> <jats:p>Antimitotics that target tubulin are among the most useful chemotherapeutic drugs, but their clinical activity is often limited by the development of multidrug resistance. We recently discovered the novel small-molecule DJ101 as a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors. In this study, we determined the mechanism of action of this drug. The basis for its activity was illuminated by solving the crystal structure of DJ101 in complex with tubulin at a resolution of 2.8Å. Investigations of the potency of DJ101 in a panel of human metastatic melanoma cell lines harboring major clinically relevant mutations defined IC50 values of 7–10 nmol/L. In cells, DJ101 disrupted microtubule networks, suppressed anchorage-dependent melanoma colony formation, and impaired cancer cell migration. In melanoma-bearing mice, DJ101 administration inhibited tumor growth and reduced lung metastasis in the absence of observable toxicity. DJ101 also completely inhibited tumor growth in a paclitaxel-resistant xenograft mouse model of human prostate cancer (PC-3/TxR), where paclitaxel was minimally effective. Our findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation tubulin inhibitor for cancer therapy.</jats:p> <jats:p>Significance: These findings offer preclinical proof of concept for the continued development of DJ101 as a next-generation antitubulin drug for cancer therapy. Cancer Res; 78(1); 265–77. ©2017 AACR.</jats:p> A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance Cancer Research |
| spellingShingle | Arnst, Kinsie E., Wang, Yuxi, Hwang, Dong-Jin, Xue, Yi, Costello, Terry, Hamilton, David, Chen, Qiang, Yang, Jinliang, Park, Frank, Dalton, James T., Miller, Duane D., Li, Wei, Cancer Research, A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance, Cancer Research, Oncology |
| title | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_full | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_fullStr | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_full_unstemmed | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_short | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| title_sort | a potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance |
| title_unstemmed | A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/0008-5472.can-17-0577 |